ReviewFrontiers in public health2025
Health technology assessment of surgical robots: a mini-review of a rapidly evolving field.
Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgical robots enhance precision and enable minimally invasive procedures but pose challenges for traditional Health Technology Assessment (HTA) due to high costs, organizational disruption, and rapid iteration. Core content: This review first reviews the development trajectory of surgical robots and their applications in modern surgery. It then elaborates on the fundamental definition and value dimensions of HTA, highlighting the IDEAL framework specifically designed for evaluating complex surgical innovations and its tailored recommendations for surgical robots. Then provides a detailed analysis of specific challenges encountered in HTA of surgical robots. Discussion: This review thoroughly examines two core controversies in current assessment paradigms: the debate over the roles of randomized controlled trials (RCTs) vs. real-world evidence (RWE) in the evidence hierarchy, and the paradigm tension between traditional cost-effectiveness analysis and the broader Value-Based Healthcare (VBHC) approach. Key identified research gaps include: the lack of standardized HTA frameworks accounting for medical device characteristics, insufficient long-term patient-centered outcomes and system-level impact data. Looking ahead, the assessment of surgical robots is evolving toward dynamic, iterative "living" HTA models, urgently requiring new paradigms to evaluate AI-integrated intelligent systems and ultimately striving toward a comprehensive assessment system integrating broad value dimensions with a global perspective. Conclusion: Static HTA methods, primarily designed for pharmaceuticals, are inadequate for complex, rapidly evolving platforms like surgical robots. Establishing a more dynamic, holistic, and standardized assessment paradigm is crucial to ensure safe, effective, and cost-efficient benefit for patients and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.